Deciphera Pharmaceuticals develops drugs to overcome drug resistance and improve the lives of cancer patients. Its primary drug candidate, QINLOCK, is used to treat gastrointestinal stromal tumors and is currently in phase 3 trials for second-line GIST. The company is also developing vimseltinib and DCC-3116 for the treatment of tenosynovial giant cell tumors and RAS/RAF mutant cancers, respectively.